Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT05316675 Not yet recruiting - Acne Vulgaris Clinical Trials

Impact of Isotretinoin in Different Doses on Quality of Life

Start date: December 2022
Phase: Phase 4
Study type: Interventional

The Cardiff Acne Disability Index is a short five-item questionnaire derived from the longer Acne Disability Index.It is designed for use in teenagers and young adults with acne. It is self explanatory and can be simply handed to the patient who is asked to complete it without the need for detailed explanation( .Abdelrazik etal., 2021). .

NCT ID: NCT05296460 Not yet recruiting - Acne Vulgaris Clinical Trials

DAPSONE GEL7.5%Versus Trichloroacetic Acid 20% ON ACNE VULGARIS

Start date: September 1, 2022
Phase: Phase 4
Study type: Interventional

Acne vulgaris, a chronic inflammatory skin disorder, is one of the most prevalent diseases that effects more than 80% of the population worldwide . A variety of factors such as genetics, hormones, infections, as well as environmental factors have been identified as the causes of acne development . Acne usually generates as a result of blockage in the pilosebaceous unit (including hair follicle, hair shaft, and sebaceous gland) due to the over-produced sebum by sebaceous gland, which further triggers the excessive proliferation of the bacterium Propionibacterium acnes (P. Acnes).

NCT ID: NCT05271487 Not yet recruiting - Acne Vulgaris Clinical Trials

A Botanical Skin Care Regimen on Mild to Moderate Acne and the Microbiome

Start date: March 7, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze changes in acne and changes in the gut and skin microbiome with the use of a multi-step botanical skin care regimen in those with mild to moderate acne.

NCT ID: NCT05105334 Not yet recruiting - Atrophic Acne Scar Clinical Trials

Combined Therapy for Acne Scars

Start date: November 8, 2021
Phase: N/A
Study type: Interventional

Compare the effectiveness of nonablative fractional resurfacing to radiofrequency micrnoeedling for facial acne scars in all skin types

NCT ID: NCT05061615 Not yet recruiting - Acne Vulgaris Clinical Trials

Clinico-demographic Features of Patients With Acne Vulgaris

Start date: October 1, 2021
Phase:
Study type: Observational

The Global Burden of Disease Study 2010 found that acne vulgaris is the eight most common skin disease, with an estimated global prevalence (for all ages) of 9.38%.(1) Furthermore . Acne is a chronic inflammatory process that presents with two types of lesions clinically; non-inflammatory (closed and open) and inflammatory lesions (papules ,pustules ,nodules and post inflammatory pigmentary changes).

NCT ID: NCT05035979 Not yet recruiting - Acne Vulgaris Clinical Trials

Oral Baidi Quzhi Granule Combined With Ju Ying Cream for Acne Vulgaris

Start date: December 1, 2021
Phase: Phase 3
Study type: Interventional

We designed the study as a double-blind,randomized,controlled clinical trial.The aim of this trial is to clarify the treatment efficacy, safety, and recurrence control of BaiDi QuZhi(BDQZ) granule combined with Ju Yin(JY) cream in the treatment of acne vulgaris.

NCT ID: NCT04730414 Not yet recruiting - Acne Vulgaris Clinical Trials

Full Spectrum Hemp Observational Study

Start date: February 2021
Phase:
Study type: Observational [Patient Registry]

In westernized societies, acne vulgaris is nearly a universal skin disease afflicting 79% to 95% of the adolescent population; older than 25 years - 40% to 54% have facial blemishes and persists into middle age in 12% of women and 3% of men. Standard treatment modalities present with high risk morbidities. Charlotte's Web hemp blemish product is predicted to significantly reduce the risks mentioned above, while improving efficacy as well as imparting other skin benefits.

NCT ID: NCT04490967 Not yet recruiting - Acne Vulgaris Clinical Trials

Silymarin Cream Versus Salicylic Acid in Treatment of Acne Vulgaris

Start date: April 2021
Phase: Phase 4
Study type: Interventional

Acne vulgaris is a disease of the pilosebaceous unit that causes noninflammatory lesions (open and closed comedones), inflammatory lesions (papules, pustules, and nodules), and varying degrees of scarring. Acne vulgaris is an extremely common condition with a lifetime prevalence of approximately 85% and occurs mostly during adolescence. Acne vulgaris leads to significant morbidity that is associated with residual scarring and psychological disturbances such as poor self-image, depression, and anxiety, which leads to a negative impact on quality of life. The treatment of acne vulgaris is challenging and often chronic, with high rates of failure and numerous choices. Frequent evaluations (i.e., every 8-12 weeks) are important to enable appropriate monitoring, manage adverse effects, and evaluate for medication compliance. Topical therapies are considered one of the mainstay treatments for patients with mild-to-moderate acne.

NCT ID: NCT04224597 Not yet recruiting - Acne Vulgaris Clinical Trials

Evaluation of the Presence of Enthesitis in Patients With Acne Vulgaris

Start date: February 1, 2020
Phase:
Study type: Observational

Acne vulgaris is an inflammatory disease of the pilosebaceous unit, affecting about 85% of the young population. In the studies p. acne is a potent stimulator of the release of IFN-gamma (IFN-)) and IL-17 from CD4 + T cells, and the presence of IL-17 + cells in the perifollicular infiltrate has been shown in biopsies of inflammatory acne lesions. Therefore, acne is thought to be a Th17-related disease (1). This study was aimed to evaluate the presence of enthesitis in patients with acne vulgaris.

NCT ID: NCT03879369 Not yet recruiting - Acne Vulgaris Clinical Trials

Sexual Dysfunction in Female Patients With Adult Acne Vulgaris

Start date: May 2019
Phase:
Study type: Observational

Assessment of sexual dysfunction in adult females with acne vulgaris and its relation to other variables as quality of life, acne severity and hormonal dysfunction.